Finance

Lists
300601:SHE
Shenzhen Kangtai Biological Prods Co Ltd
CN¥12,69
-1,93%
(-0,25) 1D
14 Okt., 15:04:13 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300601...
Open
CN¥12,93
High
CN¥12,93
Low
CN¥12,59
Mkt. cap
14,45 mjd
Avg. vol.
22,39 m
Volume
13,01 m
P/E ratio
169,00
52-wk high
CN¥17,76
52-wk low
CN¥10,70
EPS
CN¥0,08
Shares outstanding
1,12 mjd
No. of employees
2 k
Open
CN¥12,93
High
CN¥12,93
Low
CN¥12,59
Mkt. cap
14,45 mjd
Avg. vol.
22,39 m
Volume
13,01 m
P/E ratio
169,00
52-wk high
CN¥17,76
52-wk low
CN¥10,70
EPS
CN¥0,08
Shares outstanding
1,12 mjd
No. of employees
2 k
News stories
From web sources and news partners
Profile
Shenzhen Kangtai Biological Products, also known as BioKangtai, is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products. Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. Wikipedia
About Shenzhen Kangtai Biological Prods Co Ltd
CEO-
Employees1,96 k
Founded08 Sep. 1992
Headquarters-
Sector-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
671,38 m
609,64 m
631,11 m
641,89 m
Cost of goods sold
110,97 m
267,74 m
182,40 m
218,78 m
Cost of revenue
110,97 m
267,74 m
182,40 m
218,78 m
Research and development expenses
123,15 m
123,35 m
84,28 m
90,88 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
291,37 m
283,35 m
302,79 m
284,34 m
Operating expense
425,29 m
428,59 m
406,24 m
402,08 m
Total operating expenses
536,26 m
696,33 m
588,65 m
620,87 m
Operating income
135,12 m
-86,69 m
42,47 m
21,03 m
Other non operating income
-375,71 k
308,38 k
-2,04 m
1,69 m
EBT including unusual items
324,22 k
45,26 m
39,95 m
1,37 m
EBT excluding unusual items
125,91 m
-104,26 m
19,66 m
-1,09 m
Income tax expense
-11,26 m
24,17 m
6,35 m
-12,75 m
Effective tax rate
-3 472,08%
53,40%
15,89%
-932,00%
Other operating expenses
3,89 m
14,05 m
6,96 m
12,14 m
Net income
11,62 m
21,17 m
33,34 m
17,05 m
Net profit margin
1,73%
3,47%
5,28%
2,66%
Earnings per share
-
-
-
-
Interest and investment income
20,88 m
13,75 m
8,72 m
9,41 m
Interest expense
-30,13 m
-30,16 m
-29,50 m
-29,76 m
Net interest expenses
-9,24 m
-16,42 m
-20,77 m
-20,35 m
Depreciation and amortization charges
-
-
-
-
EBITDA
212,79 m
11,74 m
140,90 m
126,83 m
Gain or loss from assets sale
-365,90 k
934,47 k
-
-5,69 k
AI content may include mistakes. Learn more
Google-programme